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Abstract
Homocysteine concentrations are a read-out of methionine metabolism and have been related to changes in lifespan in
animal models. In humans, high homocysteine concentrations are an important predictor of age related disease. We aimed
to explore the association of homocysteine with familial longevity by testing whether homocysteine is lower in individuals
that are genetically enriched for longevity. We measured concentrations of total homocysteine in 1907 subjects from the
Leiden Longevity Study consisting of 1309 offspring of nonagenarian siblings, who are enriched with familial factors
promoting longevity, and 598 partners thereof as population controls. We found that homocysteine was related to age,
creatinine, folate, vitamin B levels and medical history of hypertension and stroke in both groups (all p,0.001). However,
levels of homocysteine did not differ between offspring enriched for longevity and their partners, and no differences in the
age-related rise in homocysteine levels were found between groups (p for interaction 0.63). The results suggest that
homocysteine metabolism is not likely to predict familial longevity.
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Introduction
Healthy longevity is a complex phenotype determined by a mix
of genetic and environmental factors. The heritable component of
human longevity is estimated to be modest (25–30%) [1,2]. This
genetic advantage in lifespan is not explained by common disease
alleles [3], suggesting the existence of specific longevity promoting
mechanisms. In humans, little is known about the mechanisms
driving familial longevity. Data from various model organisms
suggest that longevity is promoted by alterations in insulin
signaling, metabolism and increased resistance to oxidative stress.
Recent studies have demonstrated that growth hormone, thyroid
hormone and insulin may play an important role in the control of
the key proteins that regulate maintenance of homocysteine
homeostasis. For example, Ames Dwarf mice, which lack the
pituitary hormones growth hormone, prolactin, and thyroid
stimulating hormone and show extended lifespan compared to
their wild-type counterparts, were found to exhibit upregulated
transsulfuration and low homocysteine levels, which might be
linked to enhanced cellular oxidative stress defense mechanisms
[4,5].
In humans, data regarding methionine metabolism and
longevity are sparse. Increased concentrations of homocysteine
have consistently been associated with ischemic cardiac events,
stroke, venous thrombosis, Alzheimer’s disease, osteoporosis and
depression [6–11]. In line with these associations, higher levels of
homocysteine have shown to independently predict all cause
mortality in large population cohorts [10,12,13] as well as in
clinical populations [14,15]. Particularly, in the oldest old
homocysteine has shown to be a better predictor for all cause
and cardiovascular mortality than the commonly used Framing-
ham risk score [16]. While the association between homocysteine
and disease is well established in the general population, it is
unclear whether familial longevity is also characterised by altered
homocysteine levels.
We investigated whether lower levels of homocysteine at middle
age mark familial longevity. In the Leiden Longevity Study, we
have previously shown that the offspring from long-lived
nonagenarian sibling have, at middle age, a lower mortality rate
compared to the normal population, and have a healthier
metabolic profile and lower prevalence of cardiovascular disease
compared to their partners with whom they share their
environment [17,18].
Materials and Methods
Study design and population
The Leiden Longevity Study comprises 421 families, as
described more extensively elsewhere [17]. Families were included
and regarded as enriched for familial longevity if at least two long
lived siblings were alive and fulfilled the age-criterion of 89 years
or older for males and 91 year or older for females. As no proper
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controls exist for this age group, for further studies the offspring of
these long-lived nonagenarians were included with their partners
as controls. This generation carries on average 50% of the genetic
propensity of their long lived parent and were shown to have a
lower mortality (SMR 0.65) compared with their birth cohort [17].
Their partners, with whom most had had a relationship for
decades, were included as environmentally matched controls,
thereby minimizing environmental differences between the groups
under study. We have previously shown that environmental factors
between groups, such as smoking and physical activity, did not
differ between groups [19]. There were no selection criteria on
health or demographic characteristics. In total, 1671 offspring and
744 controls were included in the Leiden Longevity Study. For the
present study, we determined homocysteine concentrations in
1907 subjects: 1309 offspring of long-lived siblings and 598
partners thereof, of whom data on comorbidity and medication
use were available. The Medical Ethical Committee of the Leiden
University Medical Center approved the study and written
informed consent was obtained from all participants.
Blood samples and homocysteine measurement
At baseline, all participants visited the study center. Non-fasted
plasma samples were taken for the determination of total
homocysteine concentration. Total homocysteine was measured
using a competitive immunoassay (Architect, Abbott Laboratories,
Illinois USA). Creatinine was measured by Kinetic Alkaline
Picrate methodology. Folate and Vitamine B12 were measured
with respectively the Abbott Architect Folate and Abbott Architect
B12 assay (Abbott, Abbott Park, USA), which use the Chemilu-
minescent Microparticle Immunoassay (CMIA) technology with
flexible assay protocols, referred to as Chemiflex. Creatine,
vitamine B12 and folate measurements were implemented on an
Abbott ci8200.
MTHFR Genotype
Genotyping of the rs1801133 in theMTHFR gene, encoding the
enzyme methyl-tetrahydrofolate-reductase, commonly known as
MTHFR C677T, was performed using Sequenom MassARRAY
iPLEXHGold. The high iPLEX primer design was performed by
entering the sequences encompassing each polymorphism into
SpectroDESIGNER provided by SequenomH, Inc. (CA, USA).
The high plex reaction protocol was used (www.sequenom.com/
iplex). The average genotype call rate for genotyped SNPs was
96.3% and the average concordance rate was 99.7% among 4%
duplicated control samples.
Comorbidity and medication use
Additional information was collected from the generation of
offspring and partners, including self-reported information on
lifestyle factors such as smoking. Information on medical history
was obtained from the participants’ treating physicians, including
history of myocardial infarction, stroke, hypertension, diabetes,
malignancy, rheumatoid arthritis and COPD. Information on
medication use was obtained from the participants’ pharmacists.
Statistical analysis
Homocysteine concentrations were normally distributed. If not
otherwise stated, data are presented as mean with standard error
of the mean (S.E.). For multivariate analyses, we used ANOVA to
Table 1. Baseline characteristics.
Characteristics Offspring Controls P-value
n=1306 n=598
Female sex, n (%) 701 (53.6) 342 (57.2) 0.13
Age, mean (SD) 59.3 (6.5) 58.6 (7.2) 0.076
History of, n (%)
Myocardial infarction 30 (2.3) 23 (3.8) 0.055
Stroke 44 (3.4) 16 (2.7) 0.42
Hypertension 296 (22.6) 161 (26.9) 0.038
Diabetes Mellitus 57 (4.4) 45 (7.5) 0.004
Malignancy 112 (8.6) 43 (7.2) 0.32
COPD 45 (3.4) 24 (4.0) 0.55
Reumatoid Arthritis 18 (1.4) 4 (0.7) 0.18
Current smoking 143 (10.9) 75 (12.5) 0.31
Creatinine (mmol/L) 81.7 (12.6) 82.1 (13.6) 0.076
Folate (nmol/L) 10.4 (6.0) 10.5 (6.3) 0.66
Vitamin B12 (pmol/L) 369.0 (141.9) 358.8 (157.6) 0.13
MTHFR C677T genotype, n (%)
677CC 537 (41.1) 245 (41.0) 0.70
677CT 570 (43.6) 278 (46.5)
677 TT 155 (11.9) 67 (11.2)
Data are presented as means with standard deviation or number and
percentage when appropriate. P values represent difference between groups as
measured by ANOVA with correction for age and sex when appropriate, or chi
square for proportion. COPD= chronic obstructive pulmonary disease.
doi:10.1371/journal.pone.0017543.t001
Table 2. Association between homocysteine concentration
and prevalence of disease history.
History of disease n
Homocysteine
(mean, SE in umol/mol) p-value
Myocardial infarction
absent 1841 12.7 (0.08) 0.14
present 53 14.1 (0.5)
Stroke
absent 1838 12.6 (0.08) 0.009
present 60 14.3 (0.5)
Hypertension
absent 1408 12.5 (0.09) 0.009
present 456 13.2 (0.2)
Diabetes Mellitus
absent 1770 12.7 (0.08) 0.19
present 102 13.4 (0.4)
Malignancy
absent 1732 12.7 (0.08) 0.62
present 155 13.0 (0.3)
COPD
absent 1812 12.7 (0.08) 0.11
present 69 13.6 (0.4)
Reumatoid Arthritis
absent 1862 12.7 (0.08) 0.26
present 22 12.0 (0.8)
Data are presented as mean with standard error. P-values obtained after linear
regression with adjustment for age and sex.
doi:10.1371/journal.pone.0017543.t002
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calculate differences between groups. For analyses of differences
between the offspring and controls, we calculated robust standard
errors to adjust for family relationship. A P-value,0.05 was
regarded statistically significant. All analyses were performed using
SPSS version 17.0. Robust standard errors were calculated using
Stata version 10.
Results
Baseline characteristics of participants are shown in Table 1. At
baseline, offspring were slightly older, had a lower prevalence of
hypertension and diabetes mellitus and a tendency towards lower
prevalence of myocardial infarction compared to controls.
Creatinine levels tended to be lower in offspring (p = 0.076),
whereas folic acid and vitamine B12 did not differ between groups.
The common C677T polymorphism in the MTHFR gene was
equally distributed between groups. Allele frequency in our cohort
was comparable to earlier reports in the Dutch population [20]
and genotype distribution was in Hardy Weinberg equilibrium.
First, we tested whether homocysteine concentrations were
related to well known determinants. Mean homocysteine concen-
tration was 12.5 mmol/L (standard deviation (SD) 2.9 mmol/L).
Mean homocysteine concentrations were 11.8 mmol/L (standard
error (SE) 0.09 mmol/L) for females, and 13.3 mmol/L (SE
0.09 mmol/L) for males (p-value for difference,0.001). Homo-
cysteine concentrations also related to calendar age, with a mean
increase of 0.06 mmol/L (SE 0.01 mmol/L) per year for women
(p,0.001), and 0.07 mmol/L (S.E.0.01) per year increase in tHcy
for men (p,0.001). Furthermore, homocysteine concentrations
were positively correlated with creatinine levels (p,0.001), folic
acid (p,0.001), vitamin B12 levels (p,0.001), and genotype of the
MTHFR C677T polymorphism (p,0.001).
We then tested whether homocysteine concentrations were
related to prevalence of disease history. Table 2 shows that
homocysteine concentrations were significantly higher when
history of stroke or hypertension was present.
Finally, we tested whether differences existed in homocysteine
concentrations between offspring and controls. Table 3 shows the
differences between offspring and partner, both crude and after
adjustment for age, sex and creatinine. No differences were found
in homocysteine concentrations between offspring and partners
(12.7 (SE 0.1) vs. 12.7 (SE 0.1) mmol/L). Furthermore, no
differences in distribution of homocysteine were found between
groups, showing the lack of difference of homocysteine between
groups across the entire range of values (Figure 1). Also, no
differences were found when stratifying for males and females
Figure 1. Cumulative distribution curve for homocysteine in offspring (n=1306) and controls (n =598). Each dot represents one
individual.
doi:10.1371/journal.pone.0017543.g001
Table 3. Homocysteine levels in offspring and controls.
Homocysteine (mmol/L)
offspring controls p-value
All
Crude 12.7 (0.1) 12.7 (0.1) 0.92
Adjusted 12.7 (0.1) 12.7 (0.1) 0.78
Males
Crude 13.4 (0.1) 13.8 (0.2) 0.13
Adjusted 13.4 (0.1) 13.6 (0.1) 0.41
Females
Crude 12.1 (0.1) 11.9 (0.2) 0.42
Adjusted 12.1 (0.1) 12.0 (0.2) 0.71
Data represent adjusted means with standard error. P-value obtained after
correction for family clusters within offspring. Adjusted data obtained after
correction for sex, age and creatinine.
doi:10.1371/journal.pone.0017543.t003
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separately. Additionally, no differences were found in the age-
related rise in homocysteine between offspring and controls (p for
interaction 0.63). In the total study population, 21 subjects had
prescriptions for folic acid or vitamin B12 supplementation.
Excluding these subjects from analysis did not influence outcomes.
To assess the effect of outlying high homocysteine values, we
repeated the analysis excluding 18 subjects with homocysteine
concentrations higher than the 99th percentile (25.78 mmol/L),
which did not materially change results (data not shown).
Discussion
In the present study we aimed to find a relationship between
familial longevity and homocysteine concentrations. We found
that homocysteine was associated with classical determinants, but
did not differ between individuals from long-lived families
compared to their environmentally matched partners, nor did
age-related increase in homocysteine concentrations.
We found a positive association between plasma homocysteine
concentrations with cardiovascular disease prevalence, and with
classical determinants of homocysteine such as age, sex, creatinine,
vitamin B12 and folate, and MTHFR genotype. These findings
implicate that homocysteine measurements were valid and show
associations that are in agreement with previous reports [10,21–23].
Unlike earlier observations of difference in glucose, lipid and
thyroid metabolism [18,19,24,25], we found no association of
levels of homocysteine with familial longevity at middle age in our
study population. This finding is in line with the recent debate on
the causality of homocysteine in cardiovascular disease. Although
homocysteine has consistently shown to predict cardiovascular
disease in prospective studies, recent meta-analyses and reviews of
the homocysteine-lowering trials showed no effect on cardiovas-
cular end points of homocysteine lowering by means of folate and
vitamin B in individuals with prior cardiovascular disease [26,27].
However, controversy on the implications of these findings for the
causal role of homocysteine in cardiovascular disease remain, for
instance because potential adverse side effects of folate and B
vitamins on atherosclerosis might undo the beneficial effects of
lowering homocysteine [28]. It has been proposed that homocys-
teine is a marker or read-out of vascular damage and that
homocysteine per se is not causally involved in the etiology of
cardiovascular disease and mortality. The data presented in the
present study support this theory. Despite the lower prevalence of
cardiovascular disease and cardiovascular risk factors in our cohort
of individuals from long-lived families, we did not find homocys-
teine concentrations to be lower in middle-aged subjects enriched
for longevity.
Genetic studies of MTHFR polymorphisms, a genetic determi-
nant of homocysteine concentrations, have shown a relationship
between MTHFR genotype and coronary heart disease [29],
although substantial heterogeneity between the results of published
studies reflected selective publication or other methodological
problems. These findings further fuel the debate on the causal role
of homocysteine in cardiovascular disease. In the present study we
used the association of MTHFR genotypes with homocysteine
concentrations in this study as positive control, to show that
homocysteine concentrations showed expected associations and is
therefore a valid measurement. Notably, we did not perform a
formal Mendelian Randomization analysis in our family based
approach as we have selected groups based on phenotypic
differences, namely longevity. Furthermore, the study was
underpowered to perform such an analysis. We do therefore not
make a claim on causal relationships (or absence thereof) based on
this genetic association. Taken together we conclude that levels of
homocysteine do not predict familial longevity.
A drawback of our study is that we did not measure other
metabolites of the methionine cycle such as methionine, cysteine
and glutathione and did therefore not fully cover the methionine
metabolism. Glutathione, the end point of the transsulfuration
pathway of homocysteine, could be of interest as it is an important
intra-cellular antioxidant and is related to aging and disease in
humans and longevity in various animal models [30–32]. Other
interesting metabolites in the methionine cycle include S-adenosyl
methionine (SAM) and S-adenosylhomocysteine (SAH), as their
ratio is a representation of methylation status, and both markers
have been associated with cardiovascular abnormalities more
strongly than homocysteine itself [33–35]. For that reason, we
cannot exclude that other differences in methionine metabolism
might be related to familial longevity. Still, given the lack of
difference in homocysteine concentrations, which represent a
central marker of methionine metabolism, we consider the
possibility of finding major differences in other metabolites to be
small.
The Leiden Longevity Study is unique in that it allows studying
us to study longevity-related factors already at middle-age. To our
knowledge, our study is the first to address homocysteine in
relation to familial longevity. In conclusion, the results suggest that
homocysteine metabolism is not likely to predict familial longevity.
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